Clinical Trial Update: A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011) [Phase 2]

View source ↗

Summary

The 52-week Phase 2 study MK0822-011 evaluating MK0822 for knee osteoarthritis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• MK0822

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoarthritis | Phase 2 | Status: TERMINATED